Metabolic Disease CROs in Japan

Japanese CRO subsidiary providing clinical monitoring, data management, and pharmacovigilance services specializing in small-to-mid-size pharma and biotech sponsors across Asia.

Labcorp Drug Development's Japanese operations providing preclinical safety assessment, bioanalytical services, and clinical trial support for regulatory submissions to PMDA and other Asian regulatory agencies.

Japanese CRO group providing clinical development, data management, biostatistics, and regulatory affairs services across Japan, China, Korea, and Southeast Asia.

IQVIA's Japanese subsidiary providing clinical operations, real-world data analytics, regulatory strategy and technology solutions with one of the largest clinical operations teams in Japan.

Kobe-based Japanese CRO and research institute specializing in preclinical safety assessment, pharmacology and drug metabolism studies with GLP-accredited facilities.

Japanese digital health and clinical research subsidiary of M3 Inc., leveraging its physician panel of 300,000+ doctors for clinical trial site identification and recruitment in Japan.

Parexel's Japanese arm offering full-service clinical development, regulatory consulting and market access services with deep PMDA submission expertise.

Japan's pioneering CRO founded in 1957 offering non-clinical safety evaluation including NHP studies, clinical Phase I-IV development, and a proprietary nasal drug delivery platform.

Japanese preclinical ADME services company providing in vitro metabolism, transporter, and drug interaction studies using human and animal tissue preparations for drug development.